@article{Harpreet Singh_Asheesh Kumar Gupta_Arvind Kumar_Amrita Mishra_Abhishek Sharma_Arun Kumar Mishra_Vikas Kumar Chaudhari_2022, title={An Up-to-Date Review on Guillain–Barre Syndrome}, volume={9}, url={https://apjhs.com/index.php/apjhs/article/view/2797}, abstractNote={<p>Guillain–Barré syndrome (GBS) is an infrequent acute paralytic polyneuropathy that impacts around one in every 1 lakh people. It can affect both children and adults. GBS is an autoimmune condition of the peripheral nervous system that is developed due to an immune-mediated response to antigens that react with the myelin sheath of peripheral nerves, causing demyelination and/or axonal injury. In serious conditions, GBS can cause respiratory failure and even death also. The treatment with intravenous immunoglobulin and/or plasmapheresis, with an aim to neutralize and dispose the circulating antibodies from the bloodstream, respectively, in addition to supportive measures to maintain motor function of nervous system is presently available.</p>}, number={4}, journal={Asian Pacific Journal of Health Sciences}, author={Harpreet Singh and Asheesh Kumar Gupta and Arvind Kumar and Amrita Mishra and Abhishek Sharma and Arun Kumar Mishra and Vikas Kumar Chaudhari}, year={2022}, month={Jun.}, pages={233–237} }